Burosumab vs conventional therapy in children with X-linked hypophosphatemia: Results of the open-label, phase 3 extension period

LM Ward; Wolfgang Högler; FH Glorieux; AA Portale; MP Whyte; CF Munns; O Nilsson; JH Simmons; R Padidela; N Namba; HI Cheong; E Sochett; K Muroya; K. Tanaka; P Pitukcheewanont; GS Gottesman; A Biggin; F Perwad; MH Chen; L Merritt; EA Imel

doi:10.1093/jbmrpl/ziad001

Burosumab vs conventional therapy in children with X-linked hypophosphatemia: Results of the open-label, phase 3 extension period

LM Ward
, Wolfgang Högler
, FH Glorieux
, AA Portale
, MP Whyte
, CF Munns
, O Nilsson
, JH Simmons
, R Padidela
, N Namba
, HI Cheong
, E Sochett
, K Muroya
, K. Tanaka
, P Pitukcheewanont
, GS Gottesman
, A Biggin
, F Perwad
, MH Chen
, L Merritt

EA Imel

Department of Pediatrics and Adolescent Medicine

Research output: Contribution to journal › Article › peer-review

Original language	English
Article number	ziad001
Number of pages	1
Journal	JBMR Plus
Volume	8
Issue number	1
DOIs	https://doi.org/10.1093/jbmrpl/ziad001
Publication status	Published - Jan 2024

Fields of science

302035 Paediatrics and adolescent medicine

Access to Document

10.1093/jbmrpl/ziad001

Cite this

Ward, LM., Högler, W., Glorieux, FH., Portale, AA., Whyte, MP., Munns, CF., Nilsson, O., Simmons, JH., Padidela, R., Namba, N., Cheong, HI., Sochett, E., Muroya, K., Tanaka, K., Pitukcheewanont, P., Gottesman, GS., Biggin, A., Perwad, F., Chen, MH., ... Imel, EA. (2024). Burosumab vs conventional therapy in children with X-linked hypophosphatemia: Results of the open-label, phase 3 extension period. JBMR Plus, 8(1), Article ziad001. https://doi.org/10.1093/jbmrpl/ziad001

@article{e17b1a0867b449ad889f2026dd8f1e97,

title = "Burosumab vs conventional therapy in children with X-linked hypophosphatemia: Results of the open-label, phase 3 extension period",

author = "LM Ward and Wolfgang H{\"o}gler and FH Glorieux and AA Portale and MP Whyte and CF Munns and O Nilsson and JH Simmons and R Padidela and N Namba and HI Cheong and E Sochett and K Muroya and K. Tanaka and P Pitukcheewanont and GS Gottesman and A Biggin and F Perwad and MH Chen and L Merritt and EA Imel",

year = "2024",

month = jan,

doi = "10.1093/jbmrpl/ziad001",

language = "English",

volume = "8",

journal = "JBMR Plus",

issn = "2473-4039",

number = "1",

}

Ward, LM, Högler, W, Glorieux, FH, Portale, AA, Whyte, MP, Munns, CF, Nilsson, O, Simmons, JH, Padidela, R, Namba, N, Cheong, HI, Sochett, E, Muroya, K, Tanaka, K, Pitukcheewanont, P, Gottesman, GS, Biggin, A, Perwad, F, Chen, MH, Merritt , L & Imel, EA 2024, 'Burosumab vs conventional therapy in children with X-linked hypophosphatemia: Results of the open-label, phase 3 extension period', JBMR Plus, vol. 8, no. 1, ziad001. https://doi.org/10.1093/jbmrpl/ziad001

TY - JOUR

T1 - Burosumab vs conventional therapy in children with X-linked hypophosphatemia

T2 - Results of the open-label, phase 3 extension period

AU - Ward, LM

AU - Högler, Wolfgang

AU - Glorieux, FH

AU - Portale, AA

AU - Whyte, MP

AU - Munns, CF

AU - Nilsson, O

AU - Simmons, JH

AU - Padidela, R

AU - Namba, N

AU - Cheong, HI

AU - Sochett, E

AU - Muroya, K

AU - Tanaka, K.

AU - Pitukcheewanont, P

AU - Gottesman, GS

AU - Biggin, A

AU - Perwad, F

AU - Chen, MH

AU - Merritt , L

AU - Imel, EA

PY - 2024/1

Y1 - 2024/1

UR - https://www.scopus.com/pages/publications/85193424229

U2 - 10.1093/jbmrpl/ziad001

DO - 10.1093/jbmrpl/ziad001

M3 - Article

C2 - 38690124

SN - 2473-4039

VL - 8

JO - JBMR Plus

JF - JBMR Plus

IS - 1

M1 - ziad001

ER -

Burosumab vs conventional therapy in children with X-linked hypophosphatemia: Results of the open-label, phase 3 extension period

Fields of science

Access to Document

Other files and links

Cite this